Background and Purpose-Intravenous thrombolysis (IVT) within 4.5 hours from symptom onset improves functional outcome in patients with acute ischemic stroke. Its use in patients with previous stroke within the preceding 3 months is contraindicated because of the assumed higher risk of intracranial hemorrhage. In addition, tissue-type plasminogen activator may itself promote neurotoxicity and blood-brain barrier disruption. However, safety and effectiveness of repeated IVT is essentially unknown in patients with early (<3 months) recurrent stroke (ERS), because they were excluded from thrombolysis trials. This article reports the largest case series of repeated IVT in ERS. Methods-We reviewed databases of prospectively collected patient data of 8 European stroke centers for the presence of patients with ERS, who received IVT for both the index stroke and ERS. Demographics, clinical and radiological data, bleeding complications, and functional outcome were analyzed. Results-We identified 19 subjects with repeated IVT in ERS. Mean age was 68±12 years, and 37% of them were female.
Everybody Gets A Second Chance -Mike and the Mechanics I ntravenous thrombolysis (IVT) with tissue-type plasminogen activator demonstrated efficacy and safety for the treatment of acute ischemic stroke for almost 20 years. Nevertheless, IVT is still underutilized. A multitude of exclusion criteria reflects the fear for intracranial hemorrhage (ICH) and limits the widespread use of IVT. However, in recent years, several registry-based studies showed that IVT can be safely and effectively administered to patients who would have been excluded if the exclusion criteria were strictly applied, 1,2 including early (<3 months) recurrent stroke (ERS). [3] [4] [5] There is a subgroup of patients with ERS, who already received IVT for their index stroke and may benefit from a repeated thrombolysis. Repeated IVT for the treatment of myocardial infarction or pulmonary embolism is safe. However, data on repeated IVT for recurrent stroke is merely based on case reports and small case series.
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We here report the largest case series of repeated IVT in patients with ERS to date.
Patients and Methods
This case series comprises patients from 8 thrombolysis-active stroke centers in Germany, Finland, and Switzerland. We searched the prospectively collected databases for acute ischemic stroke patients who were treated twice with IVT within a 90-day time period. Patients who received endovascular treatment were not included in this study. Approval was obtained from the local ethics committee of the corresponding center if legally required. Demographic and baseline data, radiological findings, functional outcome, and bleeding complications were analyzed. Symptomatic ICH was defined as ICH leading to a ≥4-point increase in the National Institutes of Health Stroke Scale score or death during hospitalization. The ABC/2 method was used to assess final infarct volume after the first IVT. 12 Data are presented as mean±SD or as median and interquartile range. Mann-Whitney test was used for 2-group comparisons.
Results
Among 7537 patients undergoing IVT, we identified 19 patients with repeated IVT for ERS. All patients received IV alteplase 0.9 mg/kg for both the index stroke and within 90 days for the ERS.
Detailed information on baseline characteristics is provided in Table 1 . Median time interval between the first and the repeated IVT was 30 days (13-50; Table 2 ). Median final infarct volume after the first IVT was 1.5 cm 3 (0.5-3.1). Functional independence (modified Rankin scale score ≤2) was achieved in 79% and in 47% of patients after the first and the repeated IVT, respectively (P<0.05; Figure) . There were no symptomatic ICHs, neither after the first nor after the repeated thrombolysis. An asymptomatic hemorrhagic infarction type 1 was detected in 1 patient (5.3%) on follow-up imaging after the first IVT. One patient died from a spontaneous rupture of a previously unidentified infrarenal aortic aneurysm within 24 hours of the repeated IVT.
Discussion
We here report the largest case series on repeated IVT in ERS. This topic is of considerable importance because of an increased recurrence risk early after the index event and growing numbers of patients undergoing thrombolysis worldwide.
Largely based on theoretical assumptions of increased bleeding risk, IVT is currently contraindicated in patients with previous stroke within the past 3 months in Europe and the United States. Taking into account the computed tomography-based study performed by Okada et al 13 showing that hemorrhagic transformation after ischemic stroke occurred no later than 1 month from the index event and because of the fact that neither recent previous stroke nor recent silent ischemia, incidentally found on pretreatment magnetic resonance imaging, was associated with an increased ICH risk in patients receiving IVT, 3, 14 the updated Japanese guidelines for the application of IV tissuetype plasminogen activator specified that only patients with a previous stroke within 1 month are ineligible for IVT. 
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However, performing IVT twice within 3 months for 2 different ischemic strokes might expose the patient to additional risks. Although tissue-type plasminogen activator is degraded within minutes, its potential detrimental effects (disruption of the blood-brain barrier and neurotoxicity) occur hours to days later and might promote life-threatening ICH and neuronal death.
In our 19 patients with stroke, we did not observe any symptomatic ICH after the first or the second IVT. Our findings are in line with the observations in all the 11 other patients with repeated IVT in ERS published to date. 4, [7] [8] [9] [10] [11] In this series, the decision to dare a repeated IVT has been motivated by the favorable clinical (modified Rankin scale score and 24-hour National Institutes of Health Stroke Scale) and radiological outcomes (small infarct volume and high recanalization rates) after the first IVT (Figure and Table 2 ). Thus, a repeated IVT to reinstate the positive results of the first one was reasonable. Functional independence was less frequent after the repeated (47%) than after the first IVT (79%) in our patients, which is in line with a recent study of 24 patients, who received repeated IVT for recurrent stroke predominantly beyond 3 months (modified Rankin scale score ≤2: 75% after first versus 42% after repeated IVT). 5 Nevertheless, favorable outcome and mortality rates after the repeated IVT are still comparable to the outcomes reported in previous thrombolysis trials systematically excluding ERS patients.
In conclusion, patients with small infarct volumes and robust improvement (to a median National Institutes of Health Stroke Scale score of 1 at 24 hours) may be considered for repeated IVT within 3 months. Studies following strict protocols and larger registries incorporating these patients might serve to identify selection criteria for the safe use of repeated IVT in ERS.
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